MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 130281 | Name: Fulzerasib

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fulzerasib, also known as IBI351 and GFH925, s an irreversibly covalent inhibitor of KRASG12C and has demonstrated promising anti-tumor activity with acceptable safety in advanced solid tumors.

Chemical Structure

Fulzerasib
Fulzerasib
CAS#2641747-54-6

Theoretical Analysis

MedKoo Cat#: 130281

Name: Fulzerasib

CAS#: 2641747-54-6

Chemical Formula: C32H30ClFN6O4

Exact Mass: 616.2001

Molecular Weight: 617.08

Elemental Analysis: C, 62.29; H, 4.90; Cl, 5.74; F, 3.08; N, 13.62; O, 10.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Fulzerasib; IBI351; IBI-351; IBI 351; GFH925; GFH-925; GFH 925;
IUPAC/Chemical Name
(4aR)-3-acryloyl-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-6-methyl-2,3,4,4a,6,8-hexahydro-1H-pyrazino[1',2':4,5]pyrazino[2,3-c][1,8]naphthyridine-5,7-dione
InChi Key
PYKBFRQMXJWLGG-OAQYLSRUSA-N
InChi Code
InChI=1S/C32H30ClFN6O4/c1-6-23(42)38-12-13-39-21(15-38)31(43)37(5)29-28(39)18-14-19(33)26(24-20(34)8-7-9-22(24)41)36-30(18)40(32(29)44)27-17(4)10-11-35-25(27)16(2)3/h6-11,14,16,21,41H,1,12-13,15H2,2-5H3/t21-/m1/s1
SMILES Code
O=C(N1CCN2C(C3=C(N=C(C(Cl)=C3)C4=C(C=CC=C4F)O)N5C6=C(N=CC=C6C)C(C)C)=C(C5=O)N(C([C@]2(C1)[H])=O)C)C=C
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
KRAS glycine-to-cysteine substitution at codon 12 (G12C) mutation is a well-recognized and increasingly promising therapeutic target with huge unmet clinical needs in NSCLC patients. Upon oral administration, KRAS G12C inhibitor IBI351 selectively targets, binds to and inhibits the activity of the KRAS G12C mutant, thereby inhibiting KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Preparing Stock Solutions

The following data is based on the product molecular weight 617.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL